Search research articles
Contact Us
Filters
Showing results (131-140 of 156) with videos related to
Page
of 16
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 1, 2006
Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure
Matthew Bidwell Goetz, Monique R Ferguson, Xueliang Han, et al.
Leukemia Research
|
April 14, 2012
Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma
M Fragioudaki, G Tsirakis, C A Pappa, et al.
HIV/AIDS (Auckland, N.Z.)
|
November 19, 2011
Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population
M Keith Rawlings, Jennifer Klein, Edna P Toubes Klingler, et al.
Medical Oncology (Northwood, London, England)
|
January 30, 2015
Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity
M G Alexandrakis, C A Pappa, M Kokonozaki, et al.
Journal of Cancer Research and Clinical Oncology
|
March 17, 2015
Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma
Michael G Alexandrakis, Ioannis K Neonakis, Constantina A Pappa, et al.
Cytokine
|
September 24, 2011
Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma
C A Pappa, G Tsirakis, P Kanellou, et al.
International Journal of Immunopathology and Pharmacology
|
May 13, 2005
Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density
M G Alexandrakis, F H Passam, C A Pappa, et al.
Hematological Oncology
|
September 16, 2011
Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma
George Tsirakis, Constantina A Pappa, Peggy Kanellou, et al.
AIDS Research and Therapy
|
April 1, 2008
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
Kimberly Y Smith, Winkler G Weinberg, Edwin DeJesus, et al.
BMC Infectious Diseases
|
June 11, 2003
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
Jeffrey P Nadler, Joseph C Gathe, Richard B Pollard, et al.
Page
of 16
Search research articles
Search
Showing results (131-140 of 156) with videos related to
Sort By:
Page
of 16
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 1, 2006
Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure
Matthew Bidwell Goetz, Monique R Ferguson, Xueliang Han, et al.
Leukemia Research
|
April 14, 2012
Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma
M Fragioudaki, G Tsirakis, C A Pappa, et al.
HIV/AIDS (Auckland, N.Z.)
|
November 19, 2011
Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population
M Keith Rawlings, Jennifer Klein, Edna P Toubes Klingler, et al.
Medical Oncology (Northwood, London, England)
|
January 30, 2015
Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity
M G Alexandrakis, C A Pappa, M Kokonozaki, et al.
Journal of Cancer Research and Clinical Oncology
|
March 17, 2015
Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma
Michael G Alexandrakis, Ioannis K Neonakis, Constantina A Pappa, et al.
Cytokine
|
September 24, 2011
Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma
C A Pappa, G Tsirakis, P Kanellou, et al.
International Journal of Immunopathology and Pharmacology
|
May 13, 2005
Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density
M G Alexandrakis, F H Passam, C A Pappa, et al.
Hematological Oncology
|
September 16, 2011
Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma
George Tsirakis, Constantina A Pappa, Peggy Kanellou, et al.
AIDS Research and Therapy
|
April 1, 2008
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
Kimberly Y Smith, Winkler G Weinberg, Edwin DeJesus, et al.
BMC Infectious Diseases
|
June 11, 2003
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
Jeffrey P Nadler, Joseph C Gathe, Richard B Pollard, et al.
Page
of 16